KeynoteBreast

Explore an Investigational Immunotherapy Trial for Breast Cancer

Our Keynote breast cancer clinical trials are studying pembrolizumab to see if it may help patients with breast cancer. Pembrolizumab is an investigational immunotherapy that targets the PD-1 pathway.

Pembrolizumab has been FDA-approved for use in certain types of cancer.

Clinical trials for breast cancer, including triple negative breast cancer (TNBC), are underway and currently enrolling patients. To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.

6

Active Trials

0

Trials Recruiting

95

US Trial Locations